In India and on the global stage as well, Biocon is a big name in the biopharmaceutical segment, and as of late, this company is doing super well already. And if you’re here to briefly know about this company, well, you’re at the right place because we’re about to begin this post about Biocon Net Worth, Owner, CEO, Head Office, and much more.
| Company name | Biocon Limited |
| Establishment year | 1978 |
| Head Office | Bengaluru |
| Owner/Founder | Kiran Mazumdar-Shaw (Founder) |
| CEO Name | Siddharth Mittal, MD & CEO |
| Industry | Biopharmaceuticals (APIs, biosimilars, novel biologics) |
| Net worth / Market cap (Oct 2025) | ₹430.35 billion |
Company Overview
If you know just a little bit about it, well, Biocon’s expansion is primarily supported by the growth of its biosimilar division, Biocon Biologics. In May 2025, the company made a significant announcement regarding access to the U.S. market for its biosimilar drug Yesintek, which will be available to more than 100 million people through the major pharmacy benefit managers and insurers. Talking specifically about their head office, well, this one is located in Bengaluru.
Biocon’s Net Worth (Market Value)
As Biocon is listed on the stock exchange, its market capitalization serves as a gauge of its overall worth. The market capitalization of Biocon is about ₹430.35 billion by 25th October 2025. In the fiscal year 2025, the company, in its consolidated financials, has declared a revenue of ₹16,470 crore and a net profit of ₹1,013 crore, which is a strong performance after the integration of the main biosimilar assets.
Future Outlook
Talking about something of very recent, well, you should know that just in May 2025, the company made an announcement regarding the wide U.S. market access of its biosimilar for ustekinumab, Yesintek, which, by major pharmacy benefit managers and insurers, would cover more than 100 million lives. In October 2025, the Canadian Health Department approved both Yesintek and Yesintek I.V., hence consolidating Biocon Biologics’ presence in North America.